New Brazilian study finds combined use of ologen and MMC in Phaco-NPDS to provide significant clinical advantages

In Brazil, 100 patients who went under Phaco-NPDS treatment from Jan 2011 to July 2017 were followed up for 12 months post-surgery to assess whether the group with both Mitomycin-C (MMC) and ologen Collagen Matrix application fares differently from the MMC-only group. While both adjuvants are individually known to be helpful in fibrosis prevention, relatively few studies exist on their co-application during surgery. The result – the double-adjuvant group demonstrated significantly higher absolute success rates, maintained lower IOPs, came back with fewer bleb failures and required fewer post-operative needling revisions when compared with the MMC only group. The authors conclude “the more favorable wound-healing response with concomitant use of ologen and MMC, compared with MMC alone, led to better IOP control at 12 months. ”

Citation: Guedes  et al. Use of a Collagen Matrix Implant as an Adjuvant in Combined Surgery Involving Phacoemulsification and Nonpenetrating Deep Sclerectomy. Journal of Glaucoma, 2019, 28(4):363-366.

Conflicts of interest: The authors reported no conflict of interest in the completion of this study.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *